David Smith, VP of Development

Newark, NJ


BioCentriq is a state-of-the-art cell & gene therapy development & manufacturing CDMO equipped with GMP suites for Phase 1-3 clinical production. BioCentriq currently operates 35,000 square feet of facilities including four, soon to be five, ISO-7 certified GMP manufacturing suites, a fully equipped process development laboratory, quality control and analytical method development laboratories, and training facilities. With over 70 scientists, engineers, analysts, and manufacturing specialists, BioCentriq has the quality systems and infrastructure required to support the release of both autologous and allogeneic drug products. BioCentriq also specializes in multiple modalities of cell therapy including T-cell, NK cell, MSC’s and others and has expertise producing vector types such as LVV, AAV & AV. BioCentriq also operate the only McKinsey Digital Capability Center designed to explore the application of industry 4.0, digital and lean manufacturing disciplines to cell therapy.

By using this website you agree to accept our Privacy Policy and Terms & Conditions